Thérèse Aurran‐Schleinitz

1.1k total citations
26 papers, 397 citations indexed

About

Thérèse Aurran‐Schleinitz is a scholar working on Pathology and Forensic Medicine, Genetics and Immunology. According to data from OpenAlex, Thérèse Aurran‐Schleinitz has authored 26 papers receiving a total of 397 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Pathology and Forensic Medicine, 14 papers in Genetics and 8 papers in Immunology. Recurrent topics in Thérèse Aurran‐Schleinitz's work include Lymphoma Diagnosis and Treatment (16 papers), Chronic Lymphocytic Leukemia Research (14 papers) and Advanced Breast Cancer Therapies (4 papers). Thérèse Aurran‐Schleinitz is often cited by papers focused on Lymphoma Diagnosis and Treatment (16 papers), Chronic Lymphocytic Leukemia Research (14 papers) and Advanced Breast Cancer Therapies (4 papers). Thérèse Aurran‐Schleinitz collaborates with scholars based in France, United States and United Kingdom. Thérèse Aurran‐Schleinitz's co-authors include Diane Coso, Daniel Olive, Jérôme Rey, Daniel Birnbaum, Olivier Rosnet, Bruno Chetaille, Emmanuel Fournier, Patrice Dubreuil, Sylvie Marchetto and Nathalie Beslu and has published in prestigious journals such as Blood, European Journal of Immunology and Virology.

In The Last Decade

Thérèse Aurran‐Schleinitz

25 papers receiving 393 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Thérèse Aurran‐Schleinitz France 12 178 152 122 109 85 26 397
Julie C. Porcher United States 8 71 0.4× 213 1.4× 69 0.6× 126 1.2× 65 0.8× 13 399
Rina Kansal United States 13 74 0.4× 170 1.1× 53 0.4× 98 0.9× 65 0.8× 27 359
Natalie Galanina United States 9 148 0.8× 164 1.1× 103 0.8× 166 1.5× 42 0.5× 20 377
Nicolò Compagno Switzerland 6 86 0.5× 70 0.5× 203 1.7× 61 0.6× 64 0.8× 11 334
Massimo Pini Italy 10 119 0.7× 128 0.8× 115 0.9× 136 1.2× 112 1.3× 26 382
Hajime Yasuda Japan 11 115 0.6× 73 0.5× 66 0.5× 111 1.0× 93 1.1× 55 366
Lidija Čevreska North Macedonia 9 169 0.9× 153 1.0× 179 1.5× 104 1.0× 147 1.7× 40 410
Françoise Delacrétaz Switzerland 9 120 0.7× 156 1.0× 32 0.3× 107 1.0× 92 1.1× 11 383
JL Huret France 6 128 0.7× 301 2.0× 91 0.7× 166 1.5× 154 1.8× 100 521
Eva Berra Italy 8 128 0.7× 268 1.8× 60 0.5× 200 1.8× 23 0.3× 15 376

Countries citing papers authored by Thérèse Aurran‐Schleinitz

Since Specialization
Citations

This map shows the geographic impact of Thérèse Aurran‐Schleinitz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thérèse Aurran‐Schleinitz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thérèse Aurran‐Schleinitz more than expected).

Fields of papers citing papers by Thérèse Aurran‐Schleinitz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thérèse Aurran‐Schleinitz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thérèse Aurran‐Schleinitz. The network helps show where Thérèse Aurran‐Schleinitz may publish in the future.

Co-authorship network of co-authors of Thérèse Aurran‐Schleinitz

This figure shows the co-authorship network connecting the top 25 collaborators of Thérèse Aurran‐Schleinitz. A scholar is included among the top collaborators of Thérèse Aurran‐Schleinitz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thérèse Aurran‐Schleinitz. Thérèse Aurran‐Schleinitz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Noël, Robin, Christophe Zemmour, Thérèse Aurran‐Schleinitz, et al.. (2023). A phase II study of lenalidomide and rituximab (R2) combination in patients with high-risk refractory/relapsed diffuse large B-cell lymphoma. Hematology. 28(1). 2207948–2207948.
2.
Aurran‐Schleinitz, Thérèse, Cécile Tomowiak, Damien Roos‐Weil, et al.. (2022). Combined Treatment with Ibrutinib and Anti-CD38 Monoclonal Antibody Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia with TP53 Aberrations: Results of the Filo Phase II Study IDA53. Blood. 140(Supplement 1). 7030–7031. 3 indexed citations
3.
Maître, Elsa, et al.. (2017). Prolymphocytic Leukemia: New Insights in Diagnosis and in Treatment. Current Oncology Reports. 19(4). 29–29. 17 indexed citations
4.
Bühler, Andreas, Thomas J. Kipps, Laura Z. Rassenti, et al.. (2016). Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial. Blood Cancer Journal. 6(3). e404–e404. 11 indexed citations
5.
Birsen, Rudy, et al.. (2016). Ibrutinib responsive central nervous system involvement in chronic lymphocytic leukemia. Blood. 127(19). 2356–2358. 20 indexed citations
6.
Grados, A., Mikaël Ebbo, E. Bernit, et al.. (2015). Sarcoidosis Occurring After Solid Cancer. Medicine. 94(28). e928–e928. 36 indexed citations
7.
Colson, Philippe, Patrick Borentain, Diane Coso, et al.. (2015). Hepatitis B virus reactivation in HBsAg-negative patients is associated with emergence of viral strains with mutated HBsAg and reverse transcriptase. Virology. 484. 354–363. 18 indexed citations
8.
Fornecker, Luc‐Matthieu, Thérèse Aurran‐Schleinitz, Anne‐Sophie Michallet, et al.. (2015). Salvage outcomes in patients with first relapse after fludarabine, cyclophosphamide, and rituximab for chronic lymphocytic leukemia: The French intergroup experience. American Journal of Hematology. 90(6). 511–514. 17 indexed citations
9.
Coso, Diane, Sylvain Garciaz, Benjamin Esterni, et al.. (2013). Large B-cell lymphomas in adolescents and young adults in comparison to adult patients: a matched-control analysis in 55 patients. Leukemia & lymphoma. 55(8). 1849–1853. 4 indexed citations
10.
Broussais‐Guillaumot, Florence, Diane Coso, Thérèse Aurran‐Schleinitz, et al.. (2013). Peripheral T-cell lymphomas: analysis of histology, staging and response to treatment of 208 cases at a single institution. Leukemia & lymphoma. 54(11). 2392–2398. 10 indexed citations
11.
Aurran‐Schleinitz, Thérèse, Rémy Castellano, Jérôme Rey, et al.. (2012). Primary B-CLL Resistance to NK Cell Cytotoxicity can be Overcome In Vitro and In Vivo by Priming NK Cells and Monoclonal Antibody Therapy. Journal of Clinical Immunology. 32(3). 632–646. 44 indexed citations
12.
Neste, Eric Van Den, Rémi Letestu, Thérèse Aurran‐Schleinitz, et al.. (2011). Post-remission intervention with alemtuzumab or rituximab to eradicate minimal residual disease in chronic lymphocytic leukemia: where do we stand?. Leukemia & lymphoma. 53(3). 362–370. 4 indexed citations
13.
Coso, Diane, Thérèse Aurran‐Schleinitz, Jean‐Marc Schiano de Colella, et al.. (2011). Potential Synergic Effect of Lenalidomide-Rituximab Combination: Durable Complete Remissions in Refractory Diffuse Large B Cell Lymphoma. Blood. 118(21). 4989–4989. 1 indexed citations
14.
Pasero, Christine L., Bernadette Barbarat, Sylvaine Just‐Landi, et al.. (2009). A role for HVEM, but not lymphotoxin‐β receptor, in LIGHT‐induced tumor cell death and chemokine production. European Journal of Immunology. 39(9). 2502–2514. 32 indexed citations
15.
Mohty, Mohamad, et al.. (2008). Blood dendritic cells in patients with chronic lymphocytic leukaemia. Immunobiology. 213(6). 493–498. 8 indexed citations
16.
Aurran‐Schleinitz, Thérèse, Christine Arnoulet, Ivanov Vv, et al.. (2007). Prise en charge actuelle de la leucémie lymphoïde chronique. La Revue de Médecine Interne. 29(5). 424–435. 2 indexed citations
17.
Aurran‐Schleinitz, Thérèse, Gwénaëlle Gravis, Diane Coso, et al.. (2005). “One Hour” Rituximab Infusion Is Safe and Improves Patient Care and Outpatient Unit Management.. Blood. 106(11). 4759–4759. 16 indexed citations
18.
Bouabdallah, Réda, Bruno Chetaille, Thérèse Aurran‐Schleinitz, et al.. (2001). True histiocytic lymphoma following B‐acute lymphoblastic leukaemia: case report with evidence for a common clonal origin in both neoplasms. British Journal of Haematology. 113(4). 1047–1050. 27 indexed citations
19.
Aurran‐Schleinitz, Thérèse, et al.. (1999). Early progenitor cells from human mobilized peripheral blood express low levels of the flt3 receptor, but exhibit various biological responses to flt3‐L. British Journal of Haematology. 106(2). 357–367. 5 indexed citations
20.
Marchetto, Sylvie, Emmanuel Fournier, Nathalie Beslu, et al.. (1999). SHC and SHIP phosphorylation and interaction in response to activation of the FLT3 receptor. Leukemia. 13(9). 1374–1382. 55 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Julie C. Porcher Breakdown of academic impact, for papers by Rina Kansal Breakdown of academic impact, for papers by Natalie Galanina Breakdown of academic impact, for papers by Nicolò Compagno Breakdown of academic impact, for papers by Massimo Pini Breakdown of academic impact, for papers by Hajime Yasuda Breakdown of academic impact, for papers by Lidija Čevreska Breakdown of academic impact, for papers by Françoise Delacrétaz Breakdown of academic impact, for papers by JL Huret Breakdown of academic impact, for papers by Eva Berra
Rankless by CCL
2026